PolyPeptide Group AG operate as a contract development and manufacturing company worldwide. It focuses on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development, and in generic products. It engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. The company is also involved in manufacturing peptides for commercially approved peptide therapeutics. In addition, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. Further, the company offers regulatory affair support services. The company was founded in 1952 and is headquartered in Zug, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Earnings for PolyPeptide Group AG (PPGN.SW)
Earnings in 2023 (TTM): $-67,327,907
According to PolyPeptide Group AG's latest financial reports the company's current earnings (TTM) are $-67,327,907. The earnings displayed on this page is the company's Pretax Income.
Earnings history of PolyPeptide Group AG
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-67,327,907 | $-59,463,756 |
| 2022 | $8.75 M | $8.98 M |
| 2021 | $69.18 M | $54.63 M |
| 2020 | $43.56 M | $36.22 M |
| 2019 | $34.95 M | $29.75 M |
| 2018 | $34.05 M | $27.54 M |